X:TSXTMX Group Ltd. Analysis
Data as of 2026-03-14 - not real-time
CA$49.08
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
TMX Group Limited is trading at CAD 49.08, which sits above its discounted cash‑flow fair value of CAD 45.17, implying an overvalued pricing stance. The stock’s price‑to‑earnings multiple of 32.9x far exceeds the industry average of 16.4x, while the price‑to‑book ratio of 2.87x also suggests premium valuation. Despite this, the company delivers robust fundamentals: 16.4% revenue growth, a 92.6% gross margin, and a 45.6% operating margin, underscoring strong profitability. The dividend yield of 1.79% with a 56% payout ratio is backed by solid free cash flow of CAD 530 million, indicating dividend sustainability. Technical signals are mixed – the 20‑day SMA (46.80) and 50‑day SMA (48.51) lie below the current price, yet the stock remains under the 200‑day SMA (52.46) and the trend direction is flagged as bearish, with decreasing volume and an RSI of 59.1 pointing to modest momentum.
Looking ahead, the low beta of 0.17 signals limited market‑wide volatility, but the 30‑day volatility of 37.7% and a recent max drawdown of 23.4% highlight price swings. Regulatory and sector exposure is moderate, given the exchange’s reliance on financial‑services regulation across Canada and international markets. The combination of growth‑oriented earnings, a stable dividend, and overvaluation suggests a cautious stance: short‑term pressure may persist, while medium‑ to long‑term fundamentals could support a re‑rating if the price corrects toward intrinsic value.
Looking ahead, the low beta of 0.17 signals limited market‑wide volatility, but the 30‑day volatility of 37.7% and a recent max drawdown of 23.4% highlight price swings. Regulatory and sector exposure is moderate, given the exchange’s reliance on financial‑services regulation across Canada and international markets. The combination of growth‑oriented earnings, a stable dividend, and overvaluation suggests a cautious stance: short‑term pressure may persist, while medium‑ to long‑term fundamentals could support a re‑rating if the price corrects toward intrinsic value.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Price above DCF fair value and high PE relative to peers
- Bearish trend direction with price below 200‑day SMA
- Decreasing volume indicating waning buying pressure
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Strong revenue growth and high operating margins
- Sustainable dividend supported by free cash flow
- Potential price correction toward intrinsic value
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Durable earnings growth and expanding market footprint
- Low beta and stable cash generation for dividend continuity
- Opportunity to capture upside if valuation aligns with fundamentals
Key Metrics & Analysis
Financial Health
Revenue Growth16.40%
Profit Margin24.21%
P/E Ratio32.9
ROE9.76%
ROA1.07%
Debt/Equity43.64
P/B Ratio2.9
Op. Cash FlowCA$764.8M
Free Cash FlowCA$530.0M
Industry P/E16.4
Technical Analysis
TrendBearish
RSI59.2
SupportCA$44.10
ResistanceCA$49.39
MA 20CA$46.80
MA 50CA$48.51
MA 200CA$52.46
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88
Valuation
Fair ValueCA$45.17
Target PriceCA$61.25
Upside/Downside24.80%
GradeOvervalued
TypeGrowth
Dividend Yield1.79%
Risk Assessment
Beta0.17
Volatility37.69%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.